March 11 (Reuters) - Novavax Inc NVAX.O:
NOVAVAX INC - ON MARCH 7 RECEIVED NOTICE TERMINATING ADVANCED PURCHASE AGREEMENT DATED JAN 19 2021 WITH HIS MAJESTY KING IN RIGHT OF CANADA
NOVAVAX INC - EXPECTS TO RECOGNIZE $576 MILLION AS PRODUCT REVENUE IN Q1 2025
NOVAVAX- DEAL TERMINATED DUE TO CO NOT GETTING APPROVAL FOR COVID VACCINE USING BULK ANTIGEN MADE AT BIOLOGICS MANUFACTURING CENTRE BY DEC 31 2024
Source text: https://shorturl.at/e4XSS
Further company coverage: NVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.